Plain-English translation of NCT07324304 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This is a Phase II trial testing NWRD06, an experimental DNA-based injection designed to help prevent hepatocellular carcinoma (liver cancer) from returning after surgery. Researchers will give participants three injections over 8 weeks and then monitor them closely with imaging scans over the next year and a half to see if the treatment works and is safe.
After surgery to remove liver cancer, the disease sometimes comes back. This medication is being tested as a preventive treatment—given after surgery—to help keep cancer from recurring and improve outcomes for people who have had curative treatment.
You likely qualify if…
You likely don't qualify if…
You will receive three injections of the medication at weeks 0, 4, and 8. After that, you'll return for imaging scans (CT or MRI) at weeks 12, 24, 36, 48, and 72 to check whether cancer has returned. The study follows you for up to 18 months from your first injection, or until your cancer recurs, you need new cancer treatment, or the study ends—whichever comes first.
AI-generated summary from trial data · Aug 2, 2026 · Not medical advice
China